Michel Delforge
Active 1995–2025
- 106
- Papers
- 19,655
- Citations
- 60
- h-index
- 98
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine78.2%
- Biochemistry, Genetics and Molecular Biology10%
- Immunology and Microbiology10%
- Computer Science0.3%
- Economics, Econometrics and Finance0.2%
- Neuroscience0.2%
- Other1.1%
Topics
- Multiple Myeloma Research and Treatments15.9%
- CAR-T cell therapy research9.8%
- Protein Degradation and Inhibitors7.4%
- Peptidase Inhibition and Analysis4.1%
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms2.9%
- Cancer Treatment and Pharmacology2.6%
- Other57.3%
Coauthors
- Philippe Moreau44
- Michèle Cavo31
- Meletios Α. Dimopoulos29
- Niels W.C.J. van de Donk29
- Hermann Einsele28
- Jesús F. San Miguel27
- Katja Weisel26
- María‐Victoria Mateos26
- Pieter Sonneveld26
- Sonja Zweegman24
- Hartmut Goldschmidt23
- Meral Beksaç20
- Roman Hájek19
- Heinz Ludwig18
- Annemiek Broijl16
- Aurore Perrot16
- Mario Boccadoro16
- Xavier Leleu16
- Evangelos Terpos15
- Francesca Gay15
- Fredrik Schjesvold15
- Christoph Driessen14
- Thierry Façon14
- Albert Oriol13
All papers
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Authors: Nikhil C. Munshi, Larry D. Anderson, Nina Shah, Deepu Madduri, Jesús G. Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David S. Siegel, Albert Oriol, Philippe Moreau, Ibrahim Yakoub‐Agha, Michel Delforge, Michèle Cavo, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Alessandro Rambaldi, Donna Reece, Fabio Petrocca, Monica Massaro, Jamie N. Connarn, Shari M. Kaiser, Payal Patel, Liping Huang, Timothy Campbell, Kristen Hege, Jesús F. San Miguel - New England Journal of Medicine 2021 cited by 2,424
- Teclistamab in Relapsed or Refractory Multiple Myeloma
Authors: Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun Xin Wang Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani - New England Journal of Medicine 2022 cited by 1,114
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Authors: Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Michel Delforge, Jesús G. Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre‐Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt - New England Journal of Medicine 2023 cited by 705
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Authors: Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Juul Vangsted, Hermann Einsele, Andrew Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 cited by 515
- Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Authors: Meletios Α. Dimopoulos, Philippe Moreau, Evangelos Terpos, María‐Victoria Mateos, Sonja Zweegman, Gordon Cook, Michel Delforge, Roman Hájek, Fredrik Schjesvold, Michèle Cavo, Hartmut Goldschmidt, Thierry Façon, Hermann Einsele, Mario Boccadoro, Jesús F. San Miguel, Pieter Sonneveld, Ulrich Mey - Annals of Oncology 2021 cited by 820
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Authors: Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Laurent Garderet, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Pascal Lenain, Margaret Macro, Claire Mathiot, Frédérique Orsini‐Piocelle, Aurore Perrot, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet 2019 cited by 953
- Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Authors: Heinz Ludwig, Evangelos Terpos, Niels W.C.J. van de Donk, María‐Victoria Mateos, Philippe Moreau, Melitios-Athanasios Dimopoulos, Michel Delforge, Paula Rodríguez‐Otero, Jesús F. San Miguel, Kwee Yong, Francesca Gay, Hermann Einsele, Roberto Mina, Jo Caers, Christoph Driessen, Pellegrino Musto, Sonja Zweegman, Monika Engelhardt, Gordon Cook, Katja Weisel, Annemiek Broijl, Meral Beksaç, Jelena Bila, Fredrik Schjesvold, Michèle Cavo, Roman Hájek, Cyrille Touzeau, Mario Boccadoro, Pieter Sonneveld - The Lancet Oncology 2023 cited by 178
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Authors: María‐Victoria Mateos, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Mohamad Mohty, Michèle Cavo, Ravi Vij, Joanne Lindsey-Hill, Dominik Dytfeld, Emanuele Angelucci, Aurore Perrot, Reuben Benjamin, Niels W.C.J. van de Donk, Enrique M. Ocio, Christof Scheid, Francesca Gay, Wilfried Roeloffzen, Paula Rodríguez‐Otero, Annemiek Broijl, Anna Potamianou, Caline Sakabedoyan, Maria Semerjian, Sofia Keim, Vadim Strulev, Jordan M. Schecter, Martin Vogel, Robert Wapenaar, Tonia Nesheiwat, Jesús F. San Miguel, Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 cited by 240
- Neutrophil extracellular trap cell death requires both autophagy and superoxide generation
Authors: Quinten Remijsen, Tom Vanden Berghe, Ellen Wirawan, Bob Asselbergh, Eef Parthoens, Riet De Rycke, Sam Noppen, Michel Delforge, Jean Willems, Peter Vandenabeele - Cell Research 2010 cited by 806
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Authors: Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios Α. Dimopoulos, Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios Α. Dimopoulos, Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn and 30 more - The Lancet 2019 cited by 636
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Authors: Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, Ajay K. Nooka, Andrew J. Yee, Carol Ann Huff, Philippe Moreau, David Dingli, Craig E. Cole, Sagar Lonial, Meletios Α. Dimopoulos, A. Keith Stewart, Joshua Richter, Ravi Vij, Sascha A. Tuchman, Marc S. Raab, Katja Weisel, Michel Delforge, Robert F. Cornell, David Kaminetzky, James E. Hoffman, Luciano J. Costa, Terri L. Parker, Moshe Levy, Martin Schreder, Nathalie Meuleman, Laurent Frenzel, Mohamad Mohty, Sylvain Choquet, Gary J. Schiller, Raymond L. Comenzo, Monika Engelhardt, Thomas Illmer, Philip Vlummens, Chantal Doyen, Thierry Façon, Lionel Karlin, Aurore Perrot, Klaus Podar, Michael Kauffman, Sharon Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, Jean‐Richard Saint‐Martin, Marsha Crochiere, Hua Chang, Samir Parekh, Yosef Landesman, Jatin J. Shah, Paul G. Richardson, Sundar Jagannath - New England Journal of Medicine 2019 cited by 673
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Authors: Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Véronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet Oncology 2021 cited by 175
- Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Authors: Niels W.C.J. van de Donk, Philippe Moreau, Alfred L. Garfall, Manisha Bhutani, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Amrita Krishnan, Michel Delforge, Danielle Trancucci, Raluca Verona, Tara Stephenson, Katherine Chastain, Surbhi Sidana - Journal of Clinical Oncology 2023 cited by 65
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Authors: Jesús F. San Miguel, Katja Weisel, Philippe Moreau, Martha Q. Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrían Alegre, Christine Chen, Michèle Cavo, Laurent Garderet, Valentina Ivanova, Joaquín Martínez‐López, Andrew R. Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Meletios Α. Dimopoulos - The Lancet Oncology 2013 cited by 799
- Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.
Authors: Alfred L. Garfall, Ajay K. Nooka, Niels W.C.J. van de Donk, Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G Martin, Laura Rosiñol, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Amrita Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana - Journal of Clinical Oncology 2024 cited by 77
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Authors: Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Michèle Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin‐Haynes, Hervé Avet‐Loiseau, Cyrille Hulin, Thierry Façon - New England Journal of Medicine 2014 cited by 786
- Multiple myeloma: patient outcomes in real‐world practice
Authors: Kwee Yong, Michel Delforge, Christoph Driessen, Leah Fink, Alain Flinois, Sebastian Gonzalez‐McQuire, Reza Safaei, Lionel Karlin, María‐Victoria Mateos, Marc S. Raab, Paul Schoen, Michèle Cavo - British Journal of Haematology 2016 cited by 321
- Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis
Authors: Efstathios D. Pagourelias, Oana Mirea, Jürgen Duchenne, Johan Van Cleemput, Michel Delforge, Jan Bogaert, Tatiana Kuznetsova, Jens‐Uwe Voigt - Circulation Cardiovascular Imaging 2017 cited by 298
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
Authors: Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, Jens Hillengaß, Xavier Leleu, Meral Beksaç, Melissa Alsina, Albert Oriol, Michèle Cavo, Enrique M. Ocio, María‐Victoria Mateos, Elizabeth O’Donnell, Ravi Vij, H M Lokhorst, Niels W.C.J. van de Donk, Chang‐Ki Min, Tomer M. Mark, Ingemar Turesson, Markus Hansson, Heinz Ludwig, Sundar Jagannath, Michel Delforge, Charalampia Kyriakou, Parameswaran Hari, Ulf‐Henrik Mellqvist, Saad Z. Usmani, Dominik Dytfeld, Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 cited by 354
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Authors: Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Hélène Caillon, Denis Caillot, Hervé Avet‐Loiseau, Michel Delforge, Thomas Dejoie, Thierry Façon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini‐Piocelle, Murielle Roussel, Jean Marc Schiano de Colella, Niels W.C.J. van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Winnie Hua, Jianping Wang, Alba Tuozzo, Carla de Boer, Melissa Rowe, Véronique Vanquickelberghe, Robin Carson, Jessica Vermeulen, Jill Corre, Pieter Sonneveld - The Lancet Oncology 2024 cited by 112
- Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Authors: Nico Gagelmann, Diderik-Jan Eikema, Simona Iacobelli, Linda Köster, Hareth Nahi, Anne‐Marie Stoppa, Tamás Masszi, Denis Caillot, Stig Lenhoff, Miklós Udvardy, Charles Crawley, William Arcese, Clara Mariette, Ann Hunter, Xavier Leleu, Martin R. Schipperus, Michel Delforge, Pietro Pioltelli, John A. Snowden, Maija Itälä‐Remes, Maurizio Musso, Anja van Biezen, Laurent Garderet, Nicolaus Kröger - Haematologica 2018 cited by 112
- CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
Authors: Shaji Kumar, Carlos Bachier, Michèle Cavo, Paolo Corradini, Michel Delforge, Wojciech Janowski, Alexander M. Lesokhin, Roberto Mina, Laura París, Laura Rosiñol, Hang Quach, Grant R. Goodman, Rin Nakamura, Divya Samineni, Vallari Shah, Elisabeth Wassner Fritsch, Jesús G. Berdeja - Journal of Clinical Oncology 2023 cited by 40
- Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Authors: Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús G. Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Paula Rodríguez‐Otero - Blood 2024 cited by 63
- Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
Authors: Larry D. Anderson, Nikhil C. Munshi, Nina Shah, Sundar Jagannath, Jesús G. Berdeja, Sagar Lonial, Noopur Raje, David S. Siegel, Yi Lin, Albert Oriol, Philippe Moreau, Ibrahim Yakoub‐Agha, Michel Delforge, Fabio Petrocca, Payal Patel, Liping Huang, Timothy Campbell, Kristen Hege, Jesús F. San Miguel, on behalf of the KarMMa Study Investigators - Journal of Clinical Oncology 2021 cited by 66
